Oxytocin and Emotion Recognition

Health Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01216605
• Other study ID #: X01A-DO1312/1-1
• Secondary ID: DO1312/1-1
• Status: Completed
• Phase: Phase 4
• First received: October 6, 2010
• Last updated: October 6, 2010
• Start date: November 2009
• Est. completion date: January 2010

Study information

• Verified date: October 2010
• Source: University Hospital Freiburg
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Ethics Committee University of Rostock
• Study type: Interventional

Clinical Trial Summary

The present study was designed to investigate the effects of a single dose of synthetic oxytocin on facial emotion recognition in healthy adult man. Pictures of emotional faces are presented very briefly for a few milliseconds in a backward-masking paradigm in order to vary the level of awareness. In a randomized placebo-controlled between-subject design, recognition performance is compared between a drug (24 IU oxytocin) and a placebo condition. We hypothesize that oxytocin enhances emotion recognition even for facial stimuli processed with limited awareness.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Males

• 18 to 40 years of age

Exclusion Criteria:

• Any psychiatric diagnosis life-time

• Somatic disease

• IQ < 85

• Smoker

• Psychoactive medication

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Health

Intervention

Drug:
• Syntocinon 24 IU

• Placebo

Locations

Country	Name	City	State
Germany	Department of PSychiatry University of Rostock	Rostock	D

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Freiburg

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Performance on a facial emotion recognition task		45 min. following drug administration	No